Brodifacoum is a 4-hydroxycoumarin anticoagulant, with a agnate approach of activity to its actual predecessors dicoumarol and warfarin. However, due to actual top authority and continued continuance of action, it is characterised as a “second generation” or “superwarfarin” anticoagulant.
Brodifacoum inhibits the agitator vitamin K epoxide reductase. This agitator is bare for the reconstitution of the vitamin K in its aeon from vitamin K-epoxide, and so brodifacoum steadily decreases the akin of alive vitamin K in the blood. Vitamin K is appropriate for the amalgam of important substances including prothrombin, which is complex in claret clotting. This disruption becomes more astringent until the claret finer loses any adeptness to clot.
In addition, brodifacoum (as with added anticoagulants in baneful doses) increases permeability of claret capillaries; the claret claret and claret itself begins to aperture from the aboriginal claret vessels. A berserk beastly will ache progressively deepening centralized bleeding, arch to shock, accident of consciousness, and eventually death.
Brodifacoum is awful baleful to mammals and birds, and acutely baleful to fish. It is a awful accumulative poison, due to its top lipophilicity and acutely apathetic elimination.